First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leukemia (CML) for almost 10 years. Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against BCR-ABL and activity against most imatinib-resistant BCR-ABL mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Guoqing, Rafiyath, Shamudheen, Liu, Delong
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000369/
https://www.ncbi.nlm.nih.gov/pubmed/21108851
http://dx.doi.org/10.1186/1756-8722-3-47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000369/
https://www.ncbi.nlm.nih.gov/pubmed/21108851
http://dx.doi.org/10.1186/1756-8722-3-47

Ejemplares similares